Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney–liver transplantation | Zendy

Delabaudière Cyrielle | Zendy; Lavayssière Laurence | Zendy; Dörr Gaëlle | Zendy; Muscari Fabrice | Zendy; Danjoux Marie | Zendy; Sallusto Federico | Zendy; Peron Jean Marie | Zendy; Bureau Christophe | Zendy; Rostaing Lionel | Zendy; Izopet Jacques | Zendy; Kamar Nassim | Zendy

Open Access

Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney–liver transplantation

Author(s) -

Delabaudière Cyrielle,

Lavayssière Laurence,

Dörr Gaëlle,

Muscari Fabrice,

Danjoux Marie,

Sallusto Federico,

Peron Jean Marie,

Bureau Christophe,

Rostaing Lionel,

Izopet Jacques,

Kamar Nassim

Publication year - 2015

Publication title -

transplant international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.998

H-Index - 82

eISSN - 1432-2277

pISSN - 0934-0874

DOI - 10.1111/tri.12428

Subject(s) - medicine , ribavirin , sofosbuvir , pegylated interferon , liver transplantation , gastroenterology , hepatitis c , combination therapy , hepatitis c virus , kidney transplantation , hepatology , interferon , transplantation , immunology , virus

Summary Fibrosing cholestatic hepatitis ( FCH ) is a classical but rare and severe form of recurrent hepatitis C virus ( HCV ) after liver transplantation. Classical anti‐ HCV therapy, that is pegylated‐interferon (peg‐interferon) and ribavirin, has been shown to have limited efficacy in treating FCH . Herein, we report on the first case of successful use of peg‐interferon, ribavirin, plus sofosbuvir to treat HCV ‐induced FCH in a combined liver–kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks after starting therapy and was maintained until 4 weeks after the end of therapy. Antiviral tolerance was good. We conclude that the use of sofosbuvir‐based anti‐ HCV therapy can be successfully used to treat FCH after a liver or combined kidney–liver transplantation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research